• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Zelluna

Less than 1K followers

ZLNA

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview
Investor consensus

Ultimovacs is a Norwegian pharmaceutical company. The company's business focus is to develop immunotherapies for various cancer conditions. Research and development are based on a self-based technological platform, where the products are mainly further developed as vaccines. The largest presence is in Europe and North America. Ultimovacs was founded in 2011 and is headquartered in Oslo.

Read more
Market cap
-
Turnover
-
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
20.8
2026

Interim report Q2'26

5.11
2026

Interim report Q3'26

11.2
2027

Annual report '26

All
Press releases
3rd party
ShowingAll content types

Regulatory press release13.07.2026, 17.08

Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial

Zelluna
Regulatory press release02.07.2026, 14.33

Zelluna ASA - Grant of Share Options

Zelluna
Regulatory press release30.06.2026, 10.12

ZLNA: Zelluna ASA awarded NOK 16 million Research Council of Norway grant

Zelluna

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release30.06.2026, 10.12

Zelluna ASA awarded NOK 16 million Research Council of Norway grant

Zelluna
Regulatory press release29.06.2026, 13.03

Zelluna ASA: Mandatory notification of trade – Return of lent shares following Private Placement

Zelluna
Regulatory press release29.06.2026, 09.59

Zelluna ASA: New share capital registered

Zelluna
Regulatory press release29.06.2026, 08.30

ZLNA: Zelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities

Zelluna
Regulatory press release29.06.2026, 08.30

Zelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities

Zelluna
Regulatory press release26.06.2026, 16.40

Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided

Zelluna
Regulatory press release18.06.2026, 11.08

Zelluna ASA: Disclosure of large shareholding

Zelluna
Regulatory press release18.06.2026, 00.27

Zelluna ASA – Mandatory notification of trade – Subscription and share lending in Private Placement

Zelluna
Regulatory press release18.06.2026, 00.21

Zelluna ASA: Private Placement and Retail Offering successfully placed

Zelluna
Regulatory press release17.06.2026, 16.46

Zelluna ASA: Contemplated Private Placement and Retail Offering to Strengthen its Position Ahead of Initial Clinical Data

Zelluna
Regulatory press release07.05.2026, 07.00

Zelluna ASA: First Quarter 2026 results

Zelluna
Regulatory press release06.05.2026, 23.18

Zelluna ASA activates first clinical site for ZIMA-101, marking entry into clinical execution

Zelluna
Regulatory press release04.05.2026, 17.58

Zelluna ASA: Invitation to First Quarter 2026 results webcast Presentation (corrected time)

Zelluna
Regulatory press release04.05.2026, 15.19

Zelluna ASA: Invitation to First Quarter 2026 results webcast Presentation

Zelluna
Press release27.04.2026, 07.07

BioStock: Zelluna entering the clinic with promising TCR-NK therapy

Zelluna
Regulatory press release23.04.2026, 09.37

Zelluna ASA – Annual General Meeting held on April 23, 2026

Zelluna
Regulatory press release08.04.2026, 11.25

Zelluna ASA - Disclosure of voting rights of Annual General Meeting

Zelluna